Stryker Corporation $SYK Shares Purchased by Novare Capital Management LLC

Novare Capital Management LLC increased its position in shares of Stryker Corporation (NYSE:SYK) by 8.8% in the fourth quarter, HoldingsChannel reports. The firm owned 38,571 shares of the medical technology company’s stock after acquiring an additional 3,134 shares during the quarter. Novare Capital Management LLC’s holdings in Stryker were worth $13,557,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Corient Private Wealth LLC raised its holdings in shares of Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Alliancebernstein L.P. grew its position in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the period. Strive Asset Management LLC acquired a new stake in Stryker during the 3rd quarter worth about $227,389,000. Credit Agricole S A purchased a new position in shares of Stryker during the 3rd quarter valued at about $194,045,000. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Stryker by 190.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock valued at $163,878,000 after buying an additional 305,640 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Canaccord Genuity Group dropped their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Needham & Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Leerink Partners began coverage on shares of Stryker in a research note on Monday, April 13th. They set an “outperform” rating and a $410.00 price objective on the stock. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is owned by company insiders.

Stryker Stock Up 0.4%

Stryker stock opened at $306.74 on Friday. The stock has a market capitalization of $117.59 billion, a PE ratio of 35.50, a price-to-earnings-growth ratio of 1.92 and a beta of 0.80. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The business has a 50 day simple moving average of $329.68 and a 200-day simple moving average of $351.73. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.